A costed menu for global evidence synthesis infrastructure puts 40 solutions at US$278.3 million. https://www.mattheneus.com/editorial/evidence-synthesis-infrastructure-costed-menu-data-duplication-investment-2026-09-21 #HTA #EvidenceSynthesis #HealthEconomics

Indices built to predict death explain little of what patients cost. Cost prediction needs a cost-based comorbidity index. https://www.mattheneus.com/editorial/cost-based-comorbidity-index-rxrisk-charlson-elixhauser-cost-prediction-2026-09-25 #HTA #HealthEconomics #RWE

In under-fives, cost-utility models still lean on utility instruments validated in adults, and most studies never flag the substitution. https://www.mattheneus.com/editorial/paediatric-under-five-cost-utility-adult-utility-instruments-reporting-gap-2026-09-25 #HTA #HealthEconomics #EvidenceSynthesis

Germany forms a ustekinumab reference-price group covering prefilled pens and syringes. https://www.mattheneus.com/editorial/g-ba-ustekinumab-reference-price-group-stage-one-parenteral-forms-2026-09-25 #HTA #Pharma #HealthEconomics

Nearly 18 hours of avoided caregiving a year, derived from patient utilities alone. How informal care spillover enters societal value. https://www.mattheneus.com/editorial/informal-care-time-spillover-societal-value-patient-utility-derivation-2026-09-18 #HTA #HealthEconomics

Three modelling choices decide the severity weight: baseline utility, age extrapolation, shortfall method. 1.2 or 1.7. https://www.mattheneus.com/editorial/nice-severity-modifier-qaly-shortfall-utility-age-extrapolation-sensitivity-2026-09-21 #HTA #HealthEconomics

Reference prices drive a 69 percent cost gap between two European economic evaluations. https://www.mattheneus.com/editorial/reference-prices-cost-analysis-transferability-economic-evaluation-2026-09-24 #HTA #HealthEconomics #EvidenceSynthesis

Research Associate in Health Economics, The University of Manchester #healtheconomics

Many cancer cost-effectiveness models claim validation, but the reporting rarely says what was actually checked. https://www.mattheneus.com/editorial/cancer-health-economic-model-validation-reporting-advishe-gap-2026-09-16 #HTA #HealthEconomics

Weight loss may offer real value in knee osteoarthritis, but UK decision-makers still lack a transferable economic evidence base. #HTA #HealthEconomics #RWE https://www.mattheneus.com/editorial/knee-osteoarthritis-weight-loss-economic-evidence-transferability-2026-09-22

New #healtheconomics #preprint in which we propose a proportionality argument for evaluation of clinical AI: that if the model leads to changes in the way patients are treated, then it must meet the evidentiary standards of that treatment.

Naloxone coverage is a marginal-return problem, not a universal target: local budgets and saturation thresholds shape value. #HTA #HealthEconomics #RWE https://www.mattheneus.com/editorial/naloxone-saturation-marginal-return-local-budget-thresholds-2026-09-22

Research Officer in Health Economics at CHEME, Bangor University, UK #healtheconomics

Vyjuvek wins conditional backing in Poland, tied to price cuts and an outcomes guarantee. https://www.mattheneus.com/editorial/aotmit-vyjuvek-conditional-reimbursement-price-outcomes-guarantee-gem3-2026-09-18 #HTA #Pharma #HealthEconomics

New paper tackles a key challenge in #healtheconomics: evaluating diagnostics & medical devices with limited comparative data. The authors use #bladdercancer diagnostics as a case study to demonstrate novel methodological approaches.

Read the article in full here 👉 bit.ly/3TJy9ck

#HEOR #modelling

Poland backs Vyjuvek only with price cuts and an outcomes guarantee, showing how uncertainty is reshaping reimbursement. #HTA #Pharma #HealthEconomics https://www.mattheneus.com/editorial/aotmit-vyjuwek-conditional-reimbursement-price-outcomes-guarantee-gem3-2026-09-18

Cochrane finds no clear reduction in anastomotic leakage from transanal tubes after rectal cancer surgery. #HTA #EvidenceSynthesis #HealthEconomics https://www.mattheneus.com/editorial/cochrane-transanal-tube-rectal-cancer-leakage-stoma-subgroup-2026-09-22

Modern radiotherapy evaluations need three separate lenses: reporting, bias and uncertainty. https://www.mattheneus.com/editorial/modern-radiotherapy-economic-evaluation-three-dimension-review-2026-09-22 #HTA #HealthEconomics #EvidenceSynthesis

Before a tissue-engineered dialysis graft reaches market, price the interventions it must prevent. https://www.mattheneus.com/editorial/tissue-engineered-dialysis-graft-intervention-threshold-early-economic-evaluation-2026-09-21 #HTA #HealthEconomics #EvidenceSynthesis

An ICU cost review arrived already outdated. See why evidence cutoffs matter for remifentanil versus fentanyl decisions. https://www.mattheneus.com/editorial/remifentanil-fentanyl-icu-economic-evidence-update-search-cutoff-2026-09-22 #HTA #HealthEconomics #EvidenceSynthesis